Patent Peace Unlocks Future of Science: Bruker & 10x Genomics End Global Legal War
- Global patent war between Bruker and 10x Genomics concludes with a landmark settlement and cross-licensing agreement.
- All international lawsuits, including those in the US, Germany, and before the European Unified Patent Court, are dismissed.
- Scientists regain uninterrupted access to vital CosMx® and GeoMx® spatial biology platforms, crucial for medical breakthroughs.
The dust has settled on a fierce global battlefield. Bruker Corporation and 10x Genomics, two titans of scientific innovation, have declared a ceasefire, ending their protracted and high-stakes patent disputes that spanned continents3, 1, 2. This landmark global settlement draws a line under multiple litigations, with all ongoing lawsuits and administrative proceedings in the United States, Germany, and before the European Unified Patent Court now withdrawn3.
The legal saga saw dramatic twists, including a European Unified Patent Court victory for Bruker's NanoString division, invalidating a key 10x Genomics patent4, countered by a significant U.S. District Court injunction against Bruker's GeoMx® products sold in the U.S.7. Now, through global patent cross-license agreements, the storm has passed, heralding a new era of focused innovation.
"We’re pleased that we have reached a worldwide settlement with 10x, putting an end to all litigation between us,” stated Mark R. Munch, Ph.D., President of the Bruker Nano Group. He emphasized this as "a great outcome for the scientific community," ensuring researchers can continue their vital work using Bruker’s CosMx® and GeoMx® spatial biology platforms without the looming shadow of legal interference in their advancements in oncology, neurobiology, and other critical fields3.
With the "distraction and expense" of these legal cases firmly in the past, both companies can now rededicate their full energies to pushing the boundaries of discovery research, translational research, and precision medicine3. The scientific world breathes a collective sigh of relief, poised to leverage these powerful technologies, like the advanced CosMx® SMI for enhanced RNA detection and AI-driven AtoMx™ software5, 8, to accelerate breakthroughs that improve the quality of human life.
References
Stay Updated!
Get the latest biotech and pharma news delivered to your inbox.